 - Male or Female; Female subject of non-reproductive potential : is eligible to participate if she is not pregnant as confirmed by a negative serum or urine human chorionic gonadotrophin hCG test, not lactating, and at least one of the following conditions applies: Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy; Postmenopausal defined as 12 months of spontaneous amenorrhea in questionable cases a blood sample with simultaneous follicle stimulating hormone FSH and estradiol levels consistent with menopause refer to laboratory reference ranges for confirmatory levels. Females on hormone replacement therapy HRT must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until one week after the last dose of study medication. a Vasectomy with documentation of azoospermia, b Male condom plus partner use of one of the contraceptive options below: Contraceptive subdermal implant that meets the standard operating procedure SOP effectiveness criteria including a 1 rate of failure per year, as stated in the product label, Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a 1 rate of failure per year, as stated in the product label, Oral Contraceptive, either combined or progestogen alone Injectable progestogen, Contraceptive vaginal ring, Percutaneous contraceptive patches. These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception. 